Proteomics signs deal to launch PromarkerD test in US market
Filed with ASX · · 3 pages · English
Proteomics International Laboratories Ltd. on 6ix
Story so far
Earlier from Proteomics International Laboratories
- Appendix 4C - March 2018 Quarterly Report
- Europe PromarkerD patent granted for diabetic kidney disease
- Underwriters take final $342,000 of Proteomics Options
- Conversion of 90% of Proteomics Options raises of $3m
- Directors Exercise PIQ Options
Later from Proteomics International Laboratories
- Proteomics signs deal with Patia for PromarkerD in Mexico
- Further information on new licence deals in USA and Mexico
- Proteomics secures major contract - nears cash flow positive
- Appendix 4C - June 2018 Quarterly Report
- Diagnostics update- Pipeline yields potential new biomarkers
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories